SOLARA ACTIVE PHARMA SCIENCES
|
SOLARA ACTIVE PHARMA SCIENCES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -1.66 | 0.13 | -157.61 | -6.16 | -16.15 |
| CEPS(Rs) | 20.73 | 24.79 | -118.69 | 22.77 | 13.83 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 280.27 | 271.04 | 258.96 | 416.43 | 423.30 |
| Tax Rate(%) | - | - | -16.08 | 50.36 | 36.02 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 13.19 | 14.99 | -6.85 | 9.27 | 6.31 |
| EBIT Margin(%) | 6.17 | 8.38 | -27.61 | 3.13 | -1.25 |
| Pre Tax Margin(%) | -0.52 | 0.04 | -35.18 | -3.10 | -7.18 |
| PAT Margin (%) | -0.52 | 0.04 | -40.83 | -1.54 | -4.60 |
| Cash Profit Margin (%) | 6.52 | 7.25 | -33.39 | 6.16 | 4.26 |
| Performance Ratios | |||||
| ROA(%) | -0.32 | 0.02 | -21.93 | -0.78 | -2.13 |
| ROE(%) | -0.63 | 0.05 | -46.64 | -1.47 | -3.75 |
| ROCE(%) | 4.61 | 6.07 | -17.29 | 1.79 | -0.67 |
| Asset Turnover(x) | 0.62 | 0.60 | 0.54 | 0.51 | 0.46 |
| Sales/Fixed Asset(x) | 0.72 | 0.73 | 0.74 | 0.80 | 0.74 |
| Working Capital/Sales(x) | -39.54 | -6.39 | -3.05 | 16.71 | 7.21 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.39 | 1.37 | 1.35 | 1.26 | 1.35 |
| Receivable days | 98.65 | 89.55 | 116.39 | 129.77 | 140.08 |
| Inventory Days | 81.95 | 89.89 | 120.63 | 143.29 | 125.26 |
| Payable days | 139.04 | 163.33 | 140.30 | 134.61 | 163.35 |
| Valuation Parameters | |||||
| PER(x) | - | 3,821.51 | - | - | - |
| PCE(x) | 20.50 | 20.68 | -2.89 | 13.29 | 44.32 |
| Price/Book(x) | 1.52 | 1.89 | 1.44 | 0.79 | 1.57 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 1.83 | 2.21 | 1.81 | 1.51 | 2.66 |
| EV/Core EBITDA(x) | 12.99 | 13.21 | -25.96 | 13.90 | 33.72 |
| EV/EBIT(x) | 28.69 | 24.58 | -6.08 | 48.07 | -213.14 |
| EV/CE(x) | 1.31 | 1.52 | 1.21 | 0.87 | 1.32 |
| M Cap / Sales | 1.38 | 1.61 | 1.04 | 0.82 | 1.89 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 6.64 | -0.40 | -10.73 | 13.83 | -21.56 |
| Core EBITDA Growth(%) | -10.11 | 338.95 | -157.41 | 56.45 | -75.89 |
| EBIT Growth(%) | -24.28 | 130.09 | -947.28 | 385.97 | -105.17 |
| PAT Growth(%) | -1,472.22 | 100.10 | -2,448.13 | 61.83 | -126.33 |
| EPS Growth(%) | -1,340.89 | 100.09 | -2,458.12 | 61.86 | -126.21 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.53 | 0.71 | 1.07 | 0.67 | 0.67 |
| Current Ratio(x) | 0.96 | 0.77 | 0.63 | 1.08 | 1.17 |
| Quick Ratio(x) | 0.60 | 0.44 | 0.34 | 0.57 | 0.62 |
| Interest Cover(x) | 0.92 | 1.00 | -3.65 | 0.50 | -0.21 |
| Total Debt/Mcap(x) | 0.32 | 0.32 | 0.75 | 0.85 | 0.43 |
Compare Financial Ratios of peers of SOLARA ACTIVE PHARMA SCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SOLARA ACTIVE PHARMA SCIENCES | ₹3,091.2 Cr | 1.2% | 25.3% | -0.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹455,634.0 Cr | -2.9% | -2.3% | 21.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹241,576.0 Cr | -1.6% | 9.8% | 51.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹184,478.0 Cr | -2.6% | -2.3% | 37.5% | Stock Analytics | |
| CIPLA | ₹111,888.0 Cr | -2.2% | -6.1% | -12.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,322.1 Cr | -0.9% | -1.8% | -9.8% | Stock Analytics | |
SOLARA ACTIVE PHARMA SCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SOLARA ACTIVE PHARMA SCIENCES | 1.2% |
25.3% |
-0.7% |
| SENSEX | -1% |
-2.6% |
-4.1% |
You may also like the below Video Courses
